DepY​med

Mr. Grill is the past Executive Director for Pharmaceutical Research & Development at Forest Research

Institute, a subsidiary of Forest Laboratories, Inc. Mr. Grill has extensive experience and knowledge in

pharmaceutical research and development including all aspects of biopharmaceutics, formulation

development, analytical development, preformulation, bioanalytical and drug metabolism as well as

significant experience in drug discovery, regulatory affairs and drug licensing with over twenty three

years of experience in the pharmaceutical / biotechnology industry. Founder and President of Advanced

Pharmaceutical Strategies, LLC, a consulting firm for drug product development working with multiple

cancer therapeutic development companies. Successful drug development achievements include a wide range of indications and a broad range of pharmaceutical dosage forms. Mr. Grill is responsible for contributing to a significant number of pharmaceutical drug product approvals within the United States and worldwide. The products within Mr. Grills impressive portfolio include Lexapro®, Namenda®, Campral®, Combunox®, Bystolic®, Savella®, Namenda XR®, Teflaro™, Daliresp™, Linzess™, Namzaric™, and Vraylar™. Continuous support of the scientific community with more than thirty presentations, abstracts and publications as well as listed inventor on multiple pharmaceutical relevant patents. Advisory Board Member for Stony Brook University - Institute of Chemical Biology & Drug Discovery, Advisor for the BioStrategy Sessions at SUNY Stony Brook – Center of Biotechnology, Member of the Bioscience Advisory Board for SUNY Farmingdale as well as a member of the Board of Directors for the Farmingdale College Foundation. Mr. Grill holds a Bachelor of Science in Biochemistry from the State University of New York at Stony Brook with graduate studies in Pharmacology/Toxicology at Saint John’s University and a Master of Business Administration from Dowling College.

President & CEO

Andreas G. Grill